We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Method Aligns Data from Tissue Slices Virtually to Expand Possibilities for 3D Analysis

By LabMedica International staff writers
Posted on 22 Aug 2023

When it comes to studying biological tissue, whether from a patient or an animal, a common approach involves surgically removing a portion of the affected tissue for analysis. More...

In laboratories across the globe, technicians meticulously slice the extracted tissue into thin sections, which are then examined under a microscope or subjected to tests that detect specific molecules. These molecular clues can aid in diagnosing conditions, guiding treatments, or even gauging the effectiveness of drugs. However, the process of analyzing each slice is resource-intensive in terms of time, money, and computational capacity. Consequently, researchers and medical professionals are often constrained to studying only a limited number of slices from various parts of the tissue. Adding to the complexity, the act of cutting, processing, and analyzing tissue slices within a lab environment causes them to undergo physical distortions. As a result, accurately understanding how these slices align and fit into the three-dimensional structure of the original tissue becomes challenging. Now, a new method revolutionizes the ability to comprehend the three-dimensional composition of tissues, including tumors or other tissue using data from just a few slices, thus allowing for a much deeper understanding of biological tissue samples.

The new method, named Gaussian Process Spatial Alignment (GPSA) which has been developed by researchers at Gladstone Institutes (San Francisco, CA, USA) has a scope extending beyond tumors, encompassing a wide array of tissues and data derived from tissue slices. This innovative method leverages a two-layer Gaussian process. In the first layer, it aligns the warped two-dimensional tissue slice onto a three-dimensional tissue model. The second layer attributes data collected from the slice, such as activated genes, to each point in the three-dimensional model. This intelligent approach effectively reverses the warping effect, resulting in a precise alignment of the slices. During this process, the GPSA model extrapolates data to fill the gaps between slices, generating a comprehensive three-dimensional "atlas" of the tissue.

A key advantage of GPSA is its versatility. Researchers can construct tissue atlases using data from slices of varying sizes, generated by diverse technologies, and captured at different scales and resolutions. Unlike previous techniques that demanded a predefined three-dimensional framework, GPSA derives this framework solely from the two-dimensional slices when an initial framework isn't available. Additionally, GPSA has the capability to merge multiple types of tissue-slice data, such as genetic activity and cellular structure, into a unified atlas. Furthermore, when applied to slices taken from the same tissue at different time points, GPSA can generate atlases that predict how each location within the tissue evolves over time. This feature could deepen our insights into aging, disease progression, and the development of different tissues within growing organisms. Presently, researchers are engaged in further analyses to further demonstrate the tool’s flexibility. For instance, they have devised an approach that budget-conscious labs can use to determine the minimum number of tissue slices required and the precise cutting locations needed for GPSA to build an informative tissue atlas.

“Say you have four slices from different locations in a person’s breast cancer tumor, and for every point on each slice you know which of 20,000 genes are turned on or off,” said Gladstone Senior Investigator Barbara Engelhardt, PhD, senior author of the study. “GPSA creates a fully query-able 3D atlas where, for any single ‘x, y, z’ coordinate, for any of the 20,000 genes, we can dive in and ask: What genes are on and off at this position in the tumor? And how certain are we in this estimate?”

Related Links:
Gladstone Institutes


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.